Register
Login:
Share:
Email Facebook Twitter


ETF Securities experts James Butterfill and Townsend Lansing: did you know you can go long and short on ETF's?


Oxford Biomedica Share Chat (OXB)



Share Price: 8.75Bid: 8.75Ask: 8.97Change: 0.00 (0.00%)No Movement on Oxford Biomed.
Spread: 0.22Spread as %: 2.51%Open: 8.96High: 9.11Low: 8.67Yesterday’s Close: 8.75


Share Discussion for Oxford Biomedica


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Trickymatters
Posts: 17
Research
Opinion:No Opinion
Price:8.75
View Thread (2)
The parliamentary review- OXB
Sat 18:56
https://www.theparliamentaryreview.co.uk/editions/healthcare/healthcare
Here's the link to the parliamentary review which Kums mentioned. It's a review of the year highlighting all the best (breakthrough technologies) and the worst of the year to date (cybersecurity attacks). Oxford Biomedica have a two page feature on page 39 and 40. It recognises them as leading lights in a market predicted to be worth hundreds of millions and suggests they are ahead of the game in an industry with high barriers to entry.
 
begger
Posts: 589
Off Topic
Opinion:No Opinion
Price:8.75
99k
Fri 19:11
Cant argue with that :)
Trickymatters
Posts: 17
Answer
Opinion:No Opinion
Price:9.11
Novartis/Sanofi/GSK- share movement
Fri 15:24
dvb247, In answer to your question about upward influences on this stock I've been watching and investing in this for a few months. Novartis, Sanofi and GSK are the really big companies that OXB are collaborating with on patented products or key elements of the biotechnology process where OXB have intellectual property. Recently this stock has taken an upward turn on news of the competitor activity for the really exciting breakthrough technology for CTL09 related to a cure for a type of leukaemia for children and young people to begin with. Maybe because our guys are so far ahead in this field. Equally a poorly researched tip from the IC suggesting a competitor can 'manufacture' faster (not like it's a drug on a conveyor belt- it's genetic modification, more of a medical procedure where our guys are ready to go) has had a downward pressure. There are a couple of smaller companies who OXB also work with and they are at stage 2 clinical trials for Parkinson's. We should hear more about the CTL09 progress next month and Kite are going for FDA approval this Autumn too. The substantial meeting is scheduled for Nov 29th. I can't find when the safety committee meeting is scheduled for. If their product gets the thumbs down there, their prospects will be poorer. Novartis got a 10/10 review at the safety committee but they have much better stats from their trials. 83% of patients (who were very ill) responded to treatment with 100% survival after five years. The competitors are Kite and Juno so far. Kite had a 43% response rate from their trials to begin with according to the coverage on this. Juno also had a weaker response rate and sadly they have suffered some fatalities from their trials.
They are also doing exciting stuff on reducing cancerous tumours- this is at stage 2 trials so we should hear more on this over the next few months I guess.
So that's the stories I look out for on the news and in specialist press. The latter (health, biotechnology publications) probably pre-empt the big news by a couple of weeks normally.
OXB end of year results are due at the end of December. You can see which firms have invested in them on their site.
Any other tips to look out for you people?
KUMS
Posts: 17,752
Premium Chat Member
Off Topic
Opinion:Strong Buy
Price:8.90
Hold tight
Fri 09:12
& take advantage of drops.

I agree with begger & few comments yesterday.
jackdaw99
Posts: 327
Answer
Opinion:No Opinion
Price:8.91
RE: RNS or Financial Report due?
Fri 08:02
If they did, do you think they would tell you?
begger
Posts: 589
Off Topic
Opinion:No Opinion
Price:8.91
ox
Thu 19:31
I think anyone can see this is just going to grow and grow with bumps along the way as normal.
dvb247
Posts: 18
Off Topic
Opinion:No Opinion
Price:8.91
RNS or Financial Report due?
Thu 19:29
Does anyone here knows of a definite date for information that will effect the SP in a positively northern direction of course?
KUMS
Posts: 17,752
Premium Chat Member
Off Topic
Opinion:Strong Buy
Price:8.94
400k shares
Thu 13:31
for 36k buy @9p has just popped up.
KUMS
Posts: 17,752
Premium Chat Member
Off Topic
Opinion:Strong Buy
Price:8.90
The Parlamentary Review
Thu 12:15
A Year in Perspective magazine 2016/17 has 2.5 pages on OXB!

Good to see.
easyp
Posts: 162
Answer
Opinion:Strong Buy
Price:8.90
RE: Positively undervalued....
Thu 09:53
Like you have invested before and stop lossed and howled on the old free motley fool as Cluckyduck. Following OXB has been a frustrating ride but now the science has been proven and approved I am content to keep on board for the long term barring black swan events.

There will still be some rampers, shorters and dumpers floating around OXB for a while yet but in the longer term it will either flourish as a business or be taken over via a bid.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.